Related Experiment Video
Updated: Jun 17, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
p53 transcriptional pathways in breast cancer: the good, the bad and the complex
Alastair M Thompson1, David P Lane
1Department of Surgery and Molecular Oncology, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. a.m.thompson@dundee.ac.uk
Abstract:
A p53 network immunohistochemically-based signature to discriminate between good and poor prognosis breast cancer would have clinical relevance, given the key role of p53 in malignancy and response to therapy. Utilizing a five-protein signature of p53/mdm2/mdm4/bcl2/p21 discriminates good-prognosis and poor-prognosis patient groups, based on the functionality of the p53 network. However, the relationship of this five-protein signature to p53 mutation, the wide range of breast cancer therapies now in use and the over-70 age group remain uncertain. Nonetheless, confirmation of the signature in two independent series suggests that this approach should be considered in further case series and in the context of clinical trials.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...